Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161563 · ClinicalTrials.gov registry record · Phase 4
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
A Phase 4 study of Prostate Cancer, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 118
- Enrollment target
- 16
- Study locations
NCT01161563 is a Phase 4 study of Prostate Cancer that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 118 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (81% lower). The trial reports 16 study locations across 12 states.
The verdict
NCT01161563, a Phase 4 study of Prostate Cancer, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 118 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.
Conditions Studied
Interventions
- DRUG Leuprolide acetate
- DRUG Triptorelin pamoate
Study Locations (16)
Florida
- Watson Investigational Site - Daytona Beach
- Watson Investigational Site - Orange City
Indiana
- Watson Investigational Site - Carmel
- Watson Investigational Site - Jeffersonville
New Jersey
- Watson Investigational Site - Mount Laurel
- Watson Investigational Site - Voorhees Township
New York
- Watson Investigational Site - Albany
- Watson Investigational Site - Syracuse
Alabama
- Watson Investigational Site - Homewood
Idaho
- Watson Investigational Site - Coeur d'Alene
Louisiana
- Watson Investigational Site - Shreveport
Nevada
- Watson Investigational Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01161563
The ClinicalTrials.gov registry entry for NCT01161563 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (81% lower). The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Leuprolide acetate is the first listed.
NCT01161563 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Florida, Indiana, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01161563 about?
NCT01161563 is a clinical study titled "Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration". The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.
What is the current status of trial NCT01161563?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 118 participants. The study started on 2010-07. Estimated completion is 2011-04.
What conditions does trial NCT01161563 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01161563?
The interventions under investigation include: Leuprolide acetate (DRUG), Triptorelin pamoate (DRUG).
Who is sponsoring clinical trial NCT01161563?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01161563 being conducted?
This trial has 16 study locations across Alabama, Florida, Idaho, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
RECRUITING · Phase 4
-
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
RECRUITING · Phase 4
-
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
RECRUITING · Phase 4
-
Gadopiclenol in Contrast Enhanced MRI of the Prostate
RECRUITING · Phase 4
-
Preop Laxatives in Robotic Urologic Surgery
RECRUITING · Phase 4
-
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.